Drugs / Talactoferrin alfa
Talactoferrin alfa
also known as
talactoferrin · LF-00 · recombinant human lactoferrin · Talactoferrin alfa (TLF) · Talactoferrina alfa · Talactoferrine alfa · Talactoferrinum alfa · TLf
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01528137 | May → Aug 2012 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +6 | Stanford University | Terminated | No outcome recorded |
| Phase 1 | NCT00923741 | Jun 2008 → Feb 2010 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT00854633 | Jun 2009 → Mar 2012 | nosocomial infection | Agennix | Unknown | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT00630656 | Apr 2008 → Aug 2009 | infectious disease with sepsis | Agennix | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01273779 | Jun 2011 → Jan 2014 | infectious disease with sepsis | Agennix | Suspended | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT00706862 | Feb 2009 → Jun 2015 | non-small cell lung carcinoma | Agennix | Unknown | No outcome recorded |
| Phase 3 | NCT00707304 | Nov 2008 → Mar 2011 | non-small cell lung carcinoma | Agennix | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talactoferrin alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630656 ↗ |
| Known as | LF-00 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108651 ↗ |
| Known as | recombinant human lactoferrin | “Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.” NCT01273779 ↗ |
| Known as | talactoferrin | “Talactoferrin alfa, a recombinant form of human lactoferrin, has similar properties and plays an important role in maintaining the gastrointestinal mucosal barrier integrity.” PMID 23425819 ↗ Mar 2013 |
| Known as | Talactoferrin alfa (TLF) | “Talactoferrin alfa (TLF) is a recombinant human lactoferrin.” NCT00923741 ↗ |
| Known as | Talactoferrina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108651 ↗ |
| Known as | Talactoferrine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108651 ↗ |
| Known as | Talactoferrinum alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108651 ↗ |
| Known as | TLf | “Twenty-one very low birth weight (VLBW <1500 g) infants received twice-daily talactoferrin (TLf, a drug designation for recombinant human lactoferrin) or its excipient by...” PMID 27234409 ↗ Jun 2016 |
| Modality | Protein / enzyme biologic | “Talactoferrin alfa, a recombinant form of human lactoferrin” PMID 23425819 ↗ Mar 2013 |
| Route | Oral | “Enterally administered talactoferrin 1.5g or placebo every 8 hrs for up to 28 days or until discharge from the ICU.” PMID 23425819 ↗ Mar 2013 |